Sign in or create an account to add this stock to your watchlist.
About Syndax Pharmaceuticals (NASDAQ:SNDX)
Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH, Genentech, Inc., Merck KGaA, Pfizer, and AstraZeneca; collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SNDX
CUSIPN/A
Phone781-419-1400
Debt
Debt-to-Equity RatioN/A
Current Ratio7.06
Quick Ratio7.06
Price-To-Earnings
Trailing P/E Ratio-3.13
Forward P/E Ratio-2.49
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.11 million
Price / Sales106.22
Cash FlowN/A
Price / CashN/A
Book Value$3.52 per share
Price / Book2.58
Profitability
EPS (Most Recent Fiscal Year)($2.90)
Net Income$-60,800,000.00
Net Margins-3,081.07%
Return on Equity-67.69%
Return on Assets-52.09%
Miscellaneous
Employees44
Outstanding Shares24,710,000
Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions
What is Syndax Pharmaceuticals' stock symbol?
Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."
How were Syndax Pharmaceuticals' earnings last quarter?
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) issued its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.96) by $0.17. The company had revenue of $0.38 million for the quarter. Syndax Pharmaceuticals had a negative return on equity of 67.69% and a negative net margin of 3,081.07%. View Syndax Pharmaceuticals' Earnings History.
When is Syndax Pharmaceuticals' next earnings date?
What price target have analysts set for SNDX?
6 analysts have issued 1-year price targets for Syndax Pharmaceuticals' stock. Their forecasts range from $20.00 to $40.00. On average, they anticipate Syndax Pharmaceuticals' stock price to reach $26.1667 in the next twelve months. View Analyst Ratings for Syndax Pharmaceuticals.
Who are some of Syndax Pharmaceuticals' key competitors?
Some companies that are related to Syndax Pharmaceuticals include Vanda Pharmaceuticals (VNDA), Amarin (AMRN), Reata Pharmaceuticals (RETA), NuCana (NCNA), Arrowhead Pharmaceuticals (ARWR), Assembly Biosciences (ASMB), UroGen Pharma (URGN), Deciphera Pharmaceuticals (DCPH), Rhythm Pharmaceuticals (RYTM), Collegium Pharmaceutical (COLL), Theratechnologies (THERF), Rocket Pharmaceuticals (RCKT), Geron (GERN), InflaRx (IFRX) and AMAG Pharmaceuticals (AMAG).
Who are Syndax Pharmaceuticals' key executives?
Syndax Pharmaceuticals' management team includes the folowing people:
- Dr. Briggs W. Morrison, CEO & Director (Age 58)
- Mr. Michael A. Metzger, Pres & COO (Age 47)
- Mr. Richard P. Shea, CFO, Treasurer & Principal Accounting Officer (Age 66)
- Dr. Michael L. Meyers M.D., Ph.D., Chief Medical Officer and Sr. VP (Age 67)
- Dr. Peter Ordentlich, Co-Founder & CTO (Age 49)
When did Syndax Pharmaceuticals IPO?
(SNDX) raised $66 million in an IPO on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.
Has Syndax Pharmaceuticals been receiving favorable news coverage?
News articles about SNDX stock have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Syndax Pharmaceuticals earned a coverage optimism score of 0.19 on Accern's scale. They also assigned headlines about the company an impact score of 45.52 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Syndax Pharmaceuticals' major shareholders?
Syndax Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.17%), JPMorgan Chase & Co. (1.73%), Dimensional Fund Advisors LP (1.61%), Millennium Management LLC (1.38%), Point72 Asset Management L.P. (1.21%) and Sphera Funds Management LTD. (1.21%). View Institutional Ownership Trends for Syndax Pharmaceuticals.
Which major investors are selling Syndax Pharmaceuticals stock?
Which major investors are buying Syndax Pharmaceuticals stock?
SNDX stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Opaleye Management Inc., Dimensional Fund Advisors LP, BlackRock Inc., Asymmetry Capital Management L.P., Sphera Funds Management LTD., JPMorgan Chase & Co. and Sofinnova Ventures Inc. View Insider Buying and Selling for Syndax Pharmaceuticals.
How do I buy shares of Syndax Pharmaceuticals?
Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syndax Pharmaceuticals' stock price today?
One share of SNDX stock can currently be purchased for approximately $9.07.
How big of a company is Syndax Pharmaceuticals?
Syndax Pharmaceuticals has a market capitalization of $220.62 million and generates $2.11 million in revenue each year. The company earns $-60,800,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. Syndax Pharmaceuticals employs 44 workers across the globe.
How can I contact Syndax Pharmaceuticals?
Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]
MarketBeat Community Rating for Syndax Pharmaceuticals (SNDX)
MarketBeat's community ratings are surveys of what our community members think about Syndax Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Syndax Pharmaceuticals in the last 12 months. Their average twelve-month price target is $26.1667, suggesting that the stock has a possible upside of 188.50%. The high price target for SNDX is $40.00 and the low price target for SNDX is $20.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $26.1667 | $26.1667 | $26.4286 | $24.2857 |
| Price Target Upside: | 188.50% upside | 116.25% upside | 189.15% upside | 122.80% upside |
Syndax Pharmaceuticals (NASDAQ:SNDX) Consensus Price Target History
Syndax Pharmaceuticals (NASDAQ:SNDX) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Syndax Pharmaceuticals (NASDAQ:SNDX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Syndax Pharmaceuticals (NASDAQ SNDX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 15.90%
Institutional Ownership Percentage: 69.55%
Syndax Pharmaceuticals (NASDAQ SNDX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/3/2018 | Peter Ordentlich | Insider | Sell | 7,500 | $15.00 | $112,500.00 | |  |
| 5/17/2017 | Peter Ordentlich | Insider | Sell | 5,000 | $15.00 | $75,000.00 | 5,000 | |
| 3/8/2016 | Ivor Royston | Director | Buy | 150,000 | $12.00 | $1,800,000.00 | | |
(Data available from 1/1/2013 forward)
Syndax Pharmaceuticals (NASDAQ SNDX) News Headlines
| Source: |
|
Syndax Pharmaceuticals (NASDAQ:SNDX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Syndax Pharmaceuticals (NASDAQ SNDX) Stock Chart for Friday, May, 25, 2018
Loading chart…
